Dopiopharm GmbH is continuing its successful partnership with Tikun Olam Europe, announcing the introduction of two more promising cannabis strains for the German market: Tikun GNC 30/1 Grapes and Cream and the previously unknown strain on the German market, Tikun Noga 27/1. These unirradiated flowers, cultivated and processed in the state-of-the-art EU-GMP certified facility in Greece, expand Dopiopharm's already established product range with two unique profiles.

Tikun GNC 30/1 Grapes and Cream is presented as a hybrid with a THC content of approximately 30% and 1% CBD. This strain is particularly known for promoting creativity, relaxation, and sleepiness, accompanied by a sweet and fruity aroma and flavor profile. The terpene spectrum of this strain includes limonene, beta-pinene, beta-caryophyllene, alpha-humulene, and linalool, among others. Patients have previously reported positive experiences using Tikun GNC 30/1 for anxiety, stress, chronic pain, and loss of appetite.

Tikun Noga 27/1 is also a hybrid strain with an active ingredient content of about 27% THC and 1% CBD. Its effects are described as focusing and relaxing, while the sweet, spicy, and earthy aroma and flavor profile add a special touch. Dominant terpenes here include limonene, beta-pinene, beta-caryophyllene, alpha-humulene, linalool, and guaiol. Patients have found Tikun Noga 27/1 helpful for chronic pain, spasticity, loss of appetite, and nausea.

As with the introduction of Erez 20/1 and Midnight 10/14, these new strains also benefit from Tikun Olam's long-standing research and extensive patient data. Interested parties can view detailed strain descriptions on the Dopiopharm website in the section for healthcare professionals.

The new strains will also be distributed via the proven Canify AG platform to ensure quick and widespread availability throughout Germany. With the introduction of Tikun GNC 30/1 and Tikun Noga 27/1, Dopiopharm is consistently expanding its offering of high-quality medical cannabis products, providing patients with additional options for individualized therapy.

‍

‍